Log in

Relevant bibliographies by topics / Serotonin and noradrenaline reuptake inhibitors

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Serotonin and noradrenaline reuptake inhibitors'

Author: Grafiati

Published: 4 June 2021

Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Serotonin and noradrenaline reuptake inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Serotonin and noradrenaline reuptake inhibitors"

1

Artigas, Francesc. "Selective Serotonin/Noradrenaline Reuptake Inhibitors (SNRIs)." CNS Drugs 4, no. 2 (August 1995): 79–89. http://dx.doi.org/10.2165/00023210-199504020-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Scott, Allan I. F. "New classes of antidepressant drugs." Advances in Psychiatric Treatment 5, no. 2 (March 1999): 104–11. http://dx.doi.org/10.1192/apt.5.2.104.

Full text

Abstract:

The January 1997 issue of this journal contained four reviews that compared tricyclic antidepressants with selective serotonin reuptake inhibitors (SSRIs) and other newer antidepressants in terms of their pharmacology (Palazidou, 1997), adverse effects, potential drug interactions and toxicity (Henry, 1997), efficacy in the prevention of relapse and recurrence (Edwards, 1997), and findings from meta-analyses (Anderson, 1997). In July 1997 reboxetine was promoted as the first selective noradrenaline reuptake inhibitor (NARI), and in October of the same year mirtazapine was promoted as the first noradrenergic and specific serotonergic antidepressant (NaSSA). Milnacipran is presently being registered by the manufacturers, after which it will be the second antidepressant drug promoted as a specific serotonin and noradrenaline reuptake inhibitor (SNRI).

APA, Harvard, Vancouver, ISO, and other styles

3

Hayashida, Ken-ichiro, and Hideaki Obata. "Strategies to Treat Chronic Pain and Strengthen Impaired Descending Noradrenergic Inhibitory System." International Journal of Molecular Sciences 20, no. 4 (February 14, 2019): 822. http://dx.doi.org/10.3390/ijms20040822.

Full text

Abstract:

Gabapentinoids (gabapentin and pregabalin) and antidepressants (tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors) are often used to treat chronic pain. The descending noradrenergic inhibitory system from the locus coeruleus (LC) to the dorsal horn of the spinal cord plays an important role in the analgesic mechanisms of these drugs. Gabapentinoids activate the LC by inhibiting the release of γ-aminobutyric acid (GABA) and inducing the release of glutamate, thereby increasing noradrenaline levels in the spinal cord. Antidepressants increase noradrenaline levels in the spinal cord by inhibiting reuptake, and accumulating noradrenaline inhibits chronic pain through α2-adrenergic receptors in the spinal cord. Recent animal studies, however, revealed that the function of the descending noradrenergic inhibitory system is impaired in chronic pain states. Other recent studies found that histone deacetylase inhibitors and antidepressants restore the impaired noradrenergic descending inhibitory system acting on noradrenergic neurons in the LC.

APA, Harvard, Vancouver, ISO, and other styles

4

Boguta, Piotr, Dariusz Juchnowicz, Paulina Wróbel-Knybel, Agnieszka Biała-Kędra, and Hanna Karakuła-Juchnowicz. "Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants." Current Problems of Psychiatry 19, no. 4 (December 1, 2018): 267–78. http://dx.doi.org/10.2478/cpp-2018-0021.

Full text

Abstract:

Abstract Introduction: Warfarin has been considered as a “gold standard” in the prevention and treatment of thromboembolic events since 1954. Since the introduction of direct oral anticoagulants in the last few years (NOAC-Non-Vitamin K antagonist Oral Anticoagulants) prescriptions volume for apixaban, edoxaban, dabigatran and rivaroxaban have been gradually surpassing warfarin. The benefits include: anticoagulation from day one, fixed daily dosing, elimination for the need of international normalised ratio (INR) monitoring, fewer interactions with food and co-administered medicines with reduced risk of bleeding and better overall life quality. Objectives: Assessing evidence for the safe use of Non-vitamin K Oral Anticoagulants (NOAC) with Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin and Noradrenaline Reuptake Inhibitors (SNRI). Method: Review of literature published between 2014 and 2016 was made using the key words: Selective Serotonin Reuptake Inhibitor, Serotonin and Noradrenaline Reuptake Inhibitors, apixaban, dabigatran, edoxaban, rivaroxaban, bleeding, interaction, depression with time description from 2014 to 2018. Evidence within the literature was then compared with guidelines from the National Institute for Health and Care Excellence (UK), British National Formulary (UK), Clinical Excellence Commission (Australia), Thrombophilia and Anticoagulation Clinic (USA) and Summaries of Product Characteristics (SPC). Results: 1. Serotonin plays a critical role in maintaining homeostasis. Use of SSRI/SNRI compromises its platelet reuptake increasing risk of bleeding. 2. Increased tolerability and safety of NOAC over Warfarin, although caution is advised when NOAC is used with SSRI/SNRI with less evidence suggesting pharmacodynamic interactions. 3. It is not recommended to use NOAC with strong CYP and P-gp inhibitors. Conclusions: With limited literature evidence, caution is advised when co-prescribed NOACs with SSRI/SNRI, especially with other cofactors and interacting medicines further increasing risk of bleeding.

APA, Harvard, Vancouver, ISO, and other styles

5

Wiffen, Philip J. "SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS (SNRIs) FOR FIBROMYALGIA SYNDROME." Journal of Pain & Palliative Care Pharmacotherapy 27, no. 2 (June 2013): 180–81. http://dx.doi.org/10.3109/15360288.2013.810899.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Montgomery, Stuart. "Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development." International Journal of Psychiatry in Clinical Practice 10, sup2 (January 2006): 5–11. http://dx.doi.org/10.1080/13651500600637049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wanot, Bartosz, Barbara Szczygieł, Wojciech Wanot, and Mariana Magerčiaková. "DEPRESSION - TYPES AND TREATMENT OF DEPRESSION." Scientific Journal of Polonia University 32, no. 1 (April 3, 2019): 121–30. http://dx.doi.org/10.23856/3216.

Full text

Abstract:

The key symptom of depression is lowering the mood, but this is not the only sign of depression. Depression is a disease in which the symptoms reach various intensities and occur in many configurations. We distinguish the following types of depression: reactive, endogenous, neurotic, anankastic, agitated, large and small, morning (subclinical and subliminal), seasonal, masked, psychotic, postpartum, drug resistant, in children and adolescents, in the elderly, involutional, organic , in bipolar disorder, dysthymia, depression and anxiety, and in somatic diseases. Psychotherapy is now a popular and effective method of treating depression. The effects of treatment after the use of antidepressants appear only after a few weeks from the beginning of therapy. Old-generation medicines: these are tricyclic antidepressants (TLPDs), inhibitors of neuromediator reuptake and monoamine oxidase enzyme (IMAO) inhibitors. The new generation of drugs is distinguished by selective serotonin reuptake inhibitors (SSRIs), selective serotonin and noradrenaline reuptake inhibitors (SNRIs), four-ring drugs, noradrenaline reuptake inhibitors, selective reversible MAO inhibitors, and drugs with other mechanisms of action. Phototherapy (treatment of light) is currently a widely accepted method of winter depression therapy. Other treatments for depression include electroconvulsive therapy and transcranial magnetic stimulation.

APA, Harvard, Vancouver, ISO, and other styles

8

Spasojevic, Natasa, Ljubica Gavrilovic, and Sladjana Dronjak. "Different behavioral effects of maprotiline and fluxilan in rats." Archives of Biological Sciences 60, no. 1 (2008): 33–39. http://dx.doi.org/10.2298/abs0801033s.

Full text

Abstract:

Serotonin and noradrenaline are involved in the mechanisms of action of most antidepressant drugs. We examined the effects of chronic treatment with maprotiline, a selective inhibitor of noradrenaline reuptake, and fluxilan, a selective inhibitor of serotonin reuptake, on the behavior of unstressed controls and chronic unpredictable mild stress (CUMS) model rats in the forced swim test (FST) and elevated plus maze test. Both selective reuptake inhibitors resulted in a significant reduction of time spent in immobility. Climbing was significantly increased in maprotiline- and swimming was exclusively elicited in the fluxilan-treated unstressed control and CUMS rats. Maprotiline-treated ani?mals displayed decreased anxiety and fluxilan-treated rats enhanced anxiety. The obtained results suggest that central noradrenergic and serotonergic systems might be affected differently during FST. The results also demonstrate that the anxiogenic effects of chronic fluxilan treatment are similar to those reported by many other studies. These differences observed for the effects of fluxilan in relation to those reported for maprotiline and probably due to the different phar?macological profiles of these drugs.

APA, Harvard, Vancouver, ISO, and other styles

9

Munir, Samman, Aqsa Shahid, Bilal Aslam, Usman Ali Ashfaq, Muhammad Sajid Hamid Akash, Muhammad Akhtar Ali, Ahmad Almatroudi, Khaled S. Allemailem, Muhammad Shahid Riaz Rajoka, and Mohsin Khurshid. "The Therapeutic Prospects of Naturally Occurring and Synthetic Indole Alkaloids for Depression and Anxiety Disorders." Evidence-Based Complementary and Alternative Medicine 2020 (October 16, 2020): 1–11. http://dx.doi.org/10.1155/2020/8836983.

Full text

Abstract:

Depression and anxiety are the most common disorders among all age groups. Several antidepressant drugs including benzodiazepine, antidepressant tricyclics, azapirone, noradrenaline reuptake inhibitors, serotonin selective reuptake inhibitors, serotonin, noradrenaline reuptake inhibitors, and monoamine oxidase inhibitors have been used to treat these psychiatric disorders. However, these antidepressants are generally synthetic agents and can cause a wide range of side effects. The potential efficacy of plant-derived alkaloids has been reviewed against various neurodegenerative diseases including Alzheimer’s disease, Huntington disease, Parkinson’s disease, schizophrenia, and epilepsy. However, data correlating the indole alkaloids and antidepressant activity are limited. Natural products, especially plants and the marine environment, are rich sources of potential new drugs. Plants possess a variety of indole alkaloids, and compounds that have an indole moiety are related to serotonin, which is a neurotransmitter that regulates brain function and cognition, which in turn alleviates anxiety, and ensures a good mood and happiness. The present review is a summary of the bioactive compounds from plants and marine sources that contain the indole moiety, which can serve as potent antidepressants. The prospects of naturally occurring as well as synthetic indole alkaloids for the amelioration of anxiety and depression-related disorders, structure-activity relationship, and their therapeutic prospects have been discussed.

APA, Harvard, Vancouver, ISO, and other styles

10

Patacchini, Arianna, and Fiammetta Cosci. "Exposure to serotonin selective reuptake inhibitors or serotonin noradrenaline reuptake inhibitors and sexual dysfunction: Results from an online survey." International Journal of Risk & Safety in Medicine 32, no. 3 (August 13, 2021): 229–42. http://dx.doi.org/10.3233/jrs-200074.

Full text

Abstract:

BACKGROUND: Post-SSRI Sexual Dysfunction (PSSD) is characterized by sexual and emotional symptoms associated to the exposure to Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Noradrenaline Reuptake Inhibitors (SNRI). OBJECTIVE: The present study provides a comprehensive picture on demographic and clinical characteristics associated to PSSD. METHODS: An online survey was run on subjects self-declaring as affected by PSSD. The survey collected socio-demographic and clinical data via questions created ad hoc and three standardized scales (Arizona Sexual Experiences Scale, Hospital Anxiety and Depression Scale, World Health Organization Wellbeing Index). RESULTS: A total of 135 subjects (115 males; mean age 31.9 ± 8.9 years) was analysed. The syndrome was more represented among young, heterosexual males after the exposure to SSRI/SNRI at relatively high doses. The major findings involved the temporal sequence of symptoms: 118 subjects had symptoms both during and after SSRI/SNRI administration, and 17 only after, thus deposing for a iatrogenic action of SSRI/SNRI. Different variables, represented by both emotional and sexual symptoms, accounted for the variability of the severity of the sexual dysfunction as well as of wellbeing. CONCLUSIONS: Based on the present results, PSSD is a complex iatrogenic syndrome in need of being further studied and understood.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Serotonin and noradrenaline reuptake inhibitors"

1

Hughes, Zoe Alexandra. "Modulation of extracellular noradrenaline in rate cortex by selective serotonin reuptake inhibitors (SSRIs)." Thesis, University College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.300168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Carlsson, Björn. "From achiral to chiral analysis of citalopram." Doctoral thesis, Linköpings universitet, Klinisk farmakologi, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-5217.

Full text

Abstract:

Within the field of depression the “monoamine hypothesis” has been the leading theory to explain the biological basis of depression. This theory proposes that the biological basis of depression is due to a deficiency in one or more of three key neurotransmitter systems, namely noradrenaline, dopamine and serotonin which are thought to mediate the therapeutic actions of virtually every known antidepressant agent. Citalopram is a selective serotonin-reuptake inhibitor (SSRI) used for the treatment of depression and anxiety disorders. Citalopram is a racemic compound, in other words composed of a 50:50 mixture of two enantiomers (S-(+)-citalopram and R-(-)-citalopram) and with one of the enantiomers (S-(+)-citalopram) accounting for the inhibitory effect. At the time of introduction of citalopram the physician needed a therapeutic drug monitoring service to identify patients with interactions, compliance problems and for handling questions concerning polymorphic enzymes and drug metabolism. An achiral analytical separation method based on solid-phase extraction followed by high-performance liquid chromatography (HPLC) was developed for routine therapeutic drug monitoring (TDM) of citalopram and its two main demethylated metabolites. As the data available on citalopram were from achiral concentration determinations and to be able to further investigate citalopram enantiomers effects and distribution, a chiral method for separation of the enantiomers of citalopram and its demethylated metabolites was established. The advances within chiral separation techniques have made measurement of the concentrations of the individual enantiomers in biological fluids possible. The process behind enantioselective separation is however not fully understood and the mechanism behind the separation can be further scrutinized by the use of multivariate methods. A study of the optimization and characterization of the separation of the enantiomers of citalopram, desmethylcitalopram and didesmethylcitalopram on an acetylated ß-cyclodextrin column, by use of two different chemometric programs - response surface modelling and sequential optimization was performed. Sequential optimization can be a quicker mean of optimizing a chromatographic separation; response surface modelling, in addition to enabling optimization of the chromatographic process, also serves as a tool for learning more about the separation mechanism. Studies of the antidepressant effect and pharmacokinetics of citalopram have been performed in adults, but the effects on children and adolescents have only been studied to a minor extent, despite the increasing use of citalopram in these age groups. A study was initiated to investigate adolescents treated for depression, with respect to the steady-state plasma concentrations of the enantiomers of citalopram and its demethylated metabolites. The ratios between the S- and R-enantiomers of citalopram and didesmethylcitalopram were in agreement with studies involving older patients. The concentrations of the S-(+)- and R-(-) enantiomers of citalopram and desmethylcitalopram were also in agreement with values from earlier studies. The results indicate that the use of oral contraceptives may have some influence on the metabolism of citalopram. This might be because of an interaction of the contraceptive hormones with the polymorphic CYP2C19 enzyme. Even though the SSRIs are considered less toxic compared with older monoamine-active drugs like the tricyclic/tetracyclic antidepressants, the risk of developing serious side effects such as ECG abnormalities and convulsions has been seen for citalopram, when larger doses have been ingested. Furthermore, fatal overdoses have been reported where citalopram alone was the cause of death. Data on the toxicity of each of the enantiomers in humans have not been reported and no data on blood levels of the enantiomers in cases of intoxication have been presented. An investigation was initiated on forensic autopsy cases where citalopram had been found at the routine screening and these cases were further analysed with enantioselective analysis to determine the blood concentrations of the enantiomers of citalopram and metabolites. Furthermore the genotyping regarding the polymorphic enzymes CYP2D6 and CYP2C19 were performed. In 53 autopsy cases, we found increasing S/R ratios with increasing concentrations of citalopram. We found also that high citalopram S/R ratio were associated with high parent drug to metabolite ratio and may be an indicator of recent intake. Only 3.8 % were found to be poor metabolizers regarding CYP2D6 and for CYP2C19 no poor metabolizer was found. Enantioselective analysis of citalopram and its metabolites can provide valuable information about the time that has elapsed between intake and death. Genotyping can be of help in specific cases but the possibility of pharmacokinetic interactions is apparently a far greater problem than genetic enzyme deficiency.
On the day of the public defence the status of article IV was: Submitted.

APA, Harvard, Vancouver, ISO, and other styles

3

Baldwin, David S., Ian M. Anderson, David J. Nutt, Christer Allgulander, Borwin Bandelow, Boer Johan A. den, David M. Christmas, et al. "Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology." Sage, 2014. https://tud.qucosa.de/id/qucosa%3A35384.

Full text

Abstract:

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

APA, Harvard, Vancouver, ISO, and other styles

4

Kirchner, Vincent. "The elderly, arginine vasopressin & selective serotonin reuptake inhibitors." Master's thesis, University of Cape Town, 1999. http://hdl.handle.net/11427/26271.

Full text

Abstract:

The association between selective serotonin reuptake inhibitors (SSRis) and hyponatraemia has been well documented, the elderly appearing to be at greatest risk. An analysis of data of hyponatraemia in the elderly using SSRis from all published cases and from the Committee on Safety of Medicines found that the mean time to detection was about 3 weeks after commencing SSRis. A wide range of time to detection (1-253 days) and non-specific symptoms suggest hyponatraemia is detected by chance rather than being specifically looked for. This is probably a sporadic, idiosyncratic phenomenon that is not dose related as A VP function determined by serum and urine concentrations was found to be normal in six elderly patients using sertraline. In the elderly there are physiological changes, a high prevalence of medical illnesses and concomitant drug use which may precipitate hyponatraemia. Together with a risk of altered water regulation in psychiatric illness this may account for the particular susceptibility of this group to hyponatraemia whilst using SSRis. AIMS & HYPOTHESIS: This dissertation will explore the physiology of Arginine V asopressin and how changes in this system along with other physiological changes in the elderly make the elderly susceptible to hyponatraemia. This problem will then be explored in the context of elderly people with depression using SSRis which are known to cause hyponatraemia. In the first part of the research section the aims are to report the published cases of hyponatraemia occurring whilst using SSRis from the United Kingdom and specifically focus on cases in people 60 years and older. Secondly to re-analyse all case reports in the literature looking only at this population. The third aim was to investigate whether dysregulation of vasopressin function in the elderly using SSRis is a sporadic or usual phenomenon. The null hypothesis is that A VP function is not disturbed by SSRis.

APA, Harvard, Vancouver, ISO, and other styles

5

Calcagno, Eleonora. "Resistance to selective serotonin reuptake inhibitors : role of serotonergic mechanisms." Thesis, Open University, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.504263.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gordon, Sevelanne. "Selective serotonin reuptake inhibitors and tricyclic antidepressants : novel immunomodulating agents." Thesis, University of Brighton, 2012. https://research.brighton.ac.uk/en/studentTheses/2cb45086-57b5-49ba-ba8e-09fe9c92f710.

Full text

Abstract:

Acute respiratory distress syndrome (ARDS) is an inflammatory disease in humans where no satisfactory therapeutic options exist. Regulation of the immune system by neurotransmitters has been identified as a possible exploitable strategy to treat inflammatory conditions. Antidepressant drugs have been found to have secondary actions including anti-inflammatory activity in a wide range of disease states in vivo. The cellular effects of these drugs that contribute to this effect have yet to be elucidated. The aim was to examine whether anti-depressants have a direct effect on the immune system or an effect on the target tissue such as lung cells. This thesis utilised both primary lung epithelium cells along with the cell lines A549, 16HBE14o- and BETIY02. The macrophage cell line RAW 264.7 was used to determine effects of anti-depressants on immune cells. Mitochondrial function was used as a measure of cell viability while morphological techniques were used to determine levels of apoptosis and necrosis. Cellular cytokine release was used as a determination of inflammation. Nitric oxide production by activated immune cells was measured using the nitrite assay and the expression of inducible nitric oxide synthase measured by Western blot. The BETIY02 cell line was found to have the most similar characteristics to primary lung epithelium cells and could be used as an effective substitute for large-scale screening and mechanistic studies especially in inflammation. Fluoxetine and desipramine reduced the inflammatory signals coming from lung cells exposed to lipopolysaccharide (LPS). In addition to this they proved effective in reducing immune cell activation as evidenced by reduced NO release following LPS exposure via a mechanism of inhibiting iN OS protein expression. Fluoxetine and desipramine exhibited anti-inflammatory effects on both the lung cells and the immune cells, identifying possible therapeutic potential for ARDS.

APA, Harvard, Vancouver, ISO, and other styles

7

Julyan, Tom Everett. "Characteristics and consequences of antenatal exposure to selective serotonin reuptake inhibitors." Thesis, University of Glasgow, 2018. http://theses.gla.ac.uk/30712/.

Full text

Abstract:

Depression is a common condition, affecting around one in 20 people worldwide. It is challenging conceptually and clinically, with treatment being ineffective for many, and significant consequences for individuals and societies alike. Depression is particularly problematic during pregnancy, where it is no less common, but poses additional difficulties. Both depression and its pharmacological treatments are associated with a range of short- and longer- term sequelae for offspring, and current data is insufficient to allow fully informed decisions to be made by mothers, midwives, or doctors. Research is affected by practical, ethical, and methodological issues, and a myriad of confounding factors, which combine to increase uncertainties over the risks and benefits of prescribing (or not). Retrospective and prospective observational studies accompany epidemiological data linkage and meta- analyses involving millions of subjects, in contributing to both current knowledge and testable hypotheses to inform future directions for research, while clinical and preclinical studies with smaller sample sizes provide invaluable and complementary details. However, significant gaps remain, not least in delivering optimal care to each individual mother and baby. While the overall emerging picture appears reassuring to some, others acknowledge that we do not even possess all the pieces of the puzzle yet. There remains an urgent need for more comprehensive and relevant data. This thesis presents the findings from a series of pilot studies on evaluating the characteristics and consequences of antenatal exposure to selective serotonin reuptake inhibitors. Up to one in 10 women in the general Scottish population may be exposed to an antidepressant at some point during pregnancy, but adverse outcomes may be related more to underlying maternal depression, rather than its pharmacological treatment. We highlight areas of both intelligence and ignorance, and make proposals for future research.

APA, Harvard, Vancouver, ISO, and other styles

8

Ashbury, Janet E. "Selective serotonin reuptake inhibitors (SSRIs) and breast cancer : a record linkage study." Thesis, Kingston, Ont. : [s.n.], 2008. http://hdl.handle.net/1974/971.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gu, Xiaobo. "Synthesis and SAR study of Meperidine Analogues as Selective Serotonin Reuptake Inhibitors (SSRIs)." ScholarWorks@UNO, 2010. http://scholarworks.uno.edu/td/1111.

Full text

Abstract:

Meperidine has been shown to have potent binding affinity for serotonin transporters (SERT) (Ki = 41 nM) and be an inhibitor of serotonin reuptake. Based upon these pharmacological results meperidine has been identified as a lead compound for the development of a novel class of serotonin-selective reuptake inhibitors (SSRIs). A variety of potent analogues of meperidine have been synthesized and evaluated in vitro as potential ligands for the serotonin transporter. Substitutions have been made on the aryl ring, the ester moiety and the piperidine nitrogen of meperidine. Potent analogues of the aryl substituted series that included 4-iodophenyl, 2-naphthyl, 3,4-dichlorophenyl and 4-biphenyl meperidine derivatives were synthesized and chosen for further optimization of the benzyl ester analogues. Benzyl ester analogues included 4-nitro, 4-methoxyl and 3,4-dichloro benzyl analogues and exhibited high potency for serotonin transporters and high selectivity over the dopamine transporter (DAT) and the norepinephrine transporter (NET). Also the N-demethylated analogues improve the binding affinity and selectivity for serotonin transporter. The analogue 4- (carboxymethoxybenzyl)-4-(4-iodophenyl) piperidine (69f), was found the most potent (Ki=0.6 nM) and selective ligand for serotonin transporter (DAT/SERT >4500; NET/SERT >4500) for the series and has been advanced to in vivo evaluation.

APA, Harvard, Vancouver, ISO, and other styles

10

Mathebe, Ntlatseng Gretta Rhoda. "Fabrication and kinetic modeling of cytochrome P4502D6 amperometric biosensors for serotonin reuptake inhibitors." Thesis, University of the Western Cape, 2005. http://hdl.handle.net/11394/1589.

Full text

Abstract:

Magister Scientiae - MSc
An amperometric biosensor was prepared by in situ deposition of cytochrome P4502D6 (CYP2D6, P4502D6) enzyme on a polyaniline (PANI)-doped glassy carbon electrode. The PANI film was electrochemically deposited on the electrode at 100 mV s-1 against Ag/AgCl. Cyclic voltammetric characterisation of the PANI film in 1 M HCl solution showed two distinct redox peaks, which prove that the PANI film was electroactive and exhibited fast reversible electrochemistry. The surface concentration and film thickness of the adsorbed electroactive species was estimated to be 1.85 x 10 -7 mol cm -2 and approximately 16 nm, respectively. Cytochrome P4502D6 was electrostatically immobilised onto the surface of the PANI film and cyclic voltammetry was used to monitor the serotonin reuptake inhibitors (fluoxetine, fluvoxamine and citalopram) in phosphate buffer solution. Fluoxetine was found to be a substrate of CYP2D6 at low concentrations but inhibits enzyme activity at high concentrations; this was consistent with uncompetitive substrate inhibition kinetics. Thus PANI-mediated electrochemistry can be used to observe monooxygenation reaction of CYP2D6.
South Africa

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Serotonin and noradrenaline reuptake inhibitors"

1

Kulin, Nathalie A. Pregnancy outcome following first trimester maternal exposure to the newer selective serotonin reuptake inhibitors. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Anchors, Michael. Safer than Phen-Fen! Rocklin, CA: Prima Pub., 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Finnerup, Nanna Brix, and Troels Staehelin Jensen. Management issues in neuropathic pain. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0133.

Full text

Abstract:

Neuropathic pain is a common complication to cancer, cancer treatment, HIV, and other conditions that may affect the somatosensory nervous system. Neuropathic pain may be present in up to 40% of cancer patients and may persist independently of the cancer and affect the quality of life in disease-free cancer survivors. Particular surgical treatment and chemotherapy may cause chronic persistent neuropathic pain in cancer survivors. The diagnosis of neuropathic pain can be challenging and requires documentation of a nervous system lesion and pain in areas of sensory changes. The pharmacological treatment may include tricyclic antidepressants, selective serotonin noradrenaline reuptake inhibitors (duloxetine or venlafaxine), calcium channel α2↓ agonists (gabapentin or pregabalin), and opioids. Topical lidocaine and capsaicin, NMDA antagonists, carbamazepine, oxcarbazepine, and cannabinoids may be indicated. Due to limited efficacy or intolerable side effects at maximal doses, combination therapy is often required and careful monitoring of effect and adverse reactions is important.

APA, Harvard, Vancouver, ISO, and other styles

4

Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Professional Communications, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Jean-François, Baladi, Menon Devindas, and Trindade Evelinda, eds. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Clare, Stanford S., ed. Selective serotonin reuptake inhibitors (SSRIs): Past, present, and future. Austin: R.G. Landes, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

1941-, Gastpar M., and Wakelin J. S, eds. Selective 5-HT reuptake inhibitors: Novel or commonplace agents? Basel: Karger, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

A, Montgomery S., ed. Selective serotonin reuptake inhibitors: the relevance of selectivity and specificityin clinical practice. CNS (Clinical Neuroscience) Publishers, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hadfield, Cynthia. Selective serotonin reuptake inhibitors and hyponatremia in the elderly: cause or coincidence? 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gastpar, M. Selective 5-Ht Reuptake Inhibitors: Novel or Commonplace Agents? (Advances in Biological Psychiatry). S. Karger Publishers (USA), 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Serotonin and noradrenaline reuptake inhibitors"

1

Kintscher, Ulrich. "Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin." In Handbook of Experimental Pharmacology, 339–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-24716-3_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Briley, Michael, and Chantal Moret. "Antidepressant Properties of Specific Serotonin—Noradrenaline Reuptake Inhibitors." In Antidepressants, 35–52. Totowa, NJ: Humana Press, 1997. http://dx.doi.org/10.1007/978-1-59259-474-0_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Morgan, Michael M., MacDonald J. Christie, Luis De Lecea, Jason C. G. Halford, Josee E. Leysen, Warren H. Meck, Catalin V. Buhusi, et al. "Serotonin-Norepinephrine Reuptake Inhibitors." In Encyclopedia of Psychopharmacology, 1209. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3562.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Saad, Ali, Patrick Nguyen, and Samir R. Belagaje. "Selective Serotonin Reuptake Inhibitors." In Ischemic Stroke Therapeutics, 209–16. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-17750-2_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lochmann, Dee, and Tara Richardson. "Selective Serotonin Reuptake Inhibitors." In Antidepressants, 135–44. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/164_2018_172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mozayani, Mojdeh, and Ashraf Mozayani. "Selective Serotonin Reuptake Inhibitors." In Handbook of Drug Interactions, 175–85. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-654-6_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Matyi, Joshua M., and JoAnn Tschanz. "Selective Serotonin Reuptake Inhibitors." In Encyclopedia of Clinical Neuropsychology, 3115–16. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_1705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Morgan, Michael M., MacDonald J. Christie, Luis De Lecea, Jason C. G. Halford, Josee E. Leysen, Warren H. Meck, Catalin V. Buhusi, et al. "Selective Serotonin Reuptake Inhibitors." In Encyclopedia of Psychopharmacology, 1197. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mozayani, Mojdeh. "Selective Serotonin Reuptake Inhibitors." In Handbook of Drug Interactions, 215–27. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-222-9_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Early, Maureen, Logan Wink, Craig Erickson, and Christopher J. McDougle. "Serotonin Reuptake Inhibitors (SRIs)." In Encyclopedia of Autism Spectrum Disorders, 2825–29. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1698-3_839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Serotonin and noradrenaline reuptake inhibitors"

1

Caragaea, Gina, Elena Truta, Ruxandra Populeanu, Mihai Ionica, Paul Schiopu, Marian Vladescu, Maria Gabriela Neicu, and Radu Macovei. "Optoelectronic method for determinating the selective serotonin reuptake inhibitors antidepressants." In Advanced Topics in Optoelectronics, Microelectronics and Nanotechnologies IX, edited by Ionica Cristea, Marian Vladescu, and Razvan D. Tamas. SPIE, 2018. http://dx.doi.org/10.1117/12.2324748.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Alzghoul, B. N., A. A. Innabi, M. E. Langston, C. J. Patel, M. Chizinga, R. Reddy, H. M. Alnuaimat, and A. Ataya. "Prevalence of Echocardiographic Pulmonary Hypertension in Patients Using Selective Serotonin and Selective Serotonin/Norepinephrine Reuptake Inhibitors." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3862.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Morante, A., A. S. Khan, and K. Oh. "Phencyclidine and Triple C Overdose Leading to Serotonin Syndrome in the Absence of Selective Serotonin Reuptake Inhibitors." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1672.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Berg, Katherine M., Marzyeh Ghassemi, Michael W. Donnino, John Marshall, and Leo Celi. "Pre-Admission Use Of Selective Serotonin Reuptake Inhibitors Is Associated With ICU Mortality." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Eayrs, KE, and Z. Gawlowski. "G233(P) An Audit of Babies Born to Mothers on Selective Serotonin Reuptake Inhibitors." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 24–26 May 2017, ICC, Birmingham. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313087.228.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Maresh, S. A., E. Kruppe, S. Vaughan, B. Alsabri, M. S. Badr, and A. Sankari. "Selective Serotonin Reuptake Inhibitors Decrease Susceptibility to Hypocapnic Central Apnea in Patients with Chronic SCI." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Guevara Velázquez, Virginia, Milagros Rosales Dedios, Paola Gudiel Arriaza, Amparo Sánchez Serrano, J. Luis Fernandez Sánchez, Carmen Martín Gómez, and Jose Carlos Morán Sánchez. "Sleep Apnoea Syndrome (SAS) in Dysthymia treated with Selective Serotonin Reuptake Inhibitors (SSRIs): profile of patients with residual excessive daytime sleepiness (EDS)." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa857.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Serotonin and noradrenaline reuptake inhibitors"

1

Gao, Mingzhou, Hui Sun, Xunshu Cheng, Hao Zhang, Zhan Gao, Yawei Cai, Dongmei Gao, and Mingqi Qiao. Current update of effectiveness and safety of selective serotonin reuptake inhibitors (SSRIs) treatment of premenstrual dysphoric disorder (2011-2021): A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!